Merus N.V.
UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands).
All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information on the company and programs, please visit Merus’ website, www.merus.nl.
Investor and Media Inquiries:
Jillian Connell
Merus N.V.
Investor Relations and Corporate Communications
617-955-4716
j.connell@merus.nl
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Atico Mining Corporation30.6.2025 22:29:54 CEST | Press release
Atico Mining Announces Execution of Loan Amendment with Trafigura to Restructure Outstanding Credit Facility
Top California Lender30.6.2025 22:02:33 CEST | Press release
Top California Lender Welcomes New Investors to Fuel Expanded Lending Capacity
Ress Life Investments A/S30.6.2025 20:20:00 CEST | Press release
Ress Life Investments A/S publishes Net Asset Value (NAV).
Barclays Bank PLC30.6.2025 19:35:11 CEST | Press release
Barclays Bank PLC: Launch of accelerated placing of shares in InPost
Novonesis (Novozymes A/S)30.6.2025 18:59:15 CEST | Press release
Transactions under Novonesis’ share buyback program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom